This trial is unknown!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Acute Promyelocytic Leukemia
and you are
between 14 and 70
years old
This is a trial in the final phase before the treatment is released on the market.
Show me locations

The purpose

The investigators design a multicenter randomized controlled trial to prove that RIF plus ATRA is possibly superior to ATO plus ATRA as consolidation and maintenance treatment for the patients with non-high-risk APL.

Provided treatments

  • Drug: Realgar-Indigo naturalis formula
  • Drug: all-trans retinoic acid
  • Drug: Arsenic trioxide
  • Drug: Hydroxyurea

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT02899169. The sponsor of the trial is First Affiliated Hospital Xi'an Jiaotong University and it is looking for 110 volunteers for the current phase.
Official trial title:
Treatment of Non-high-risk Acute Promyelocytic Leukemia With Realgar-Indigo Naturalis Formula (RIF) and All-trans Retinoid Acid (ATRA)